How protein-slayer drugs could beat some of the cruellest cancers
Momentum is building for PROTAC treatments that eliminate disease-causing proteins, including those responsible for difficult-to-treat...
Jul 9
LLS Expands its Global Master Trial for Hard-To-Treat Leukemias in Children
The Leukemia & Lymphoma Society (LLS) announced today the first pediatric patient has received treatment in a new subtrial of its...
Jun 27
Unmasking a hidden threat for optimal ALL treatment in children
Asparaginase (ASNase) remains a cornerstone of chemo regimens for ALL. But there’s a quiet threat that’s often missed: hypersensitivity...
Jun 24
FDA Grants Rare Pediatric Designation to Treatment With NEO100 in Brain Cancer
The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade gliomas, a type...
Apr 10
NHS offers new drug to stop children and teens losing hearing after chemotherapy
Our SIOPEL-6 study showed that sodium thiosulfate (Pedmarqsi) almost halves the percentage of children and teenagers who lose hearing as...
Jan 30
Menin inhibitor clinical trial puts pediatric leukemia patient in remission
“Patient response to revumenib has been good in other clinical trials,” explains Cuglievan. “But it’s also been short-lived when used...
Dec 27, 2024
Infantile Fibrosarcoma and Other Solid Tumors Respond Well to Precision Medicine
There’s new evidence that Larotrectinib (Vitrakvi), by Loxo Oncology and Bayer, is highly effective in children with newly diagnosed...
Dec 24, 2024
Why copper could be key to treating a rare childhood cancer
The survival rate for children with a rare but deadly cancer could one day be improved by adding an existing drug—which is currently used...
Dec 23, 2024
How a Penn State professor developed a cancer-fighting drug for kids
Giselle Saulnier Sholler has spent 20 years working treatments for neuroblastoma, a particularly aggressive form of early childhood...
Dec 6, 2024
Larotrectinib Is Promising for Pediatric TRK Fusion-Positive CNS Tumors
Larotrectinib led to rapid/durable responses and high disease control rates in children with TRK fusion-position central nervous system...
Nov 28, 2024